Research showed that patients with a higher level of Faecalibacterium prausnitzii and other related Firmicutes, and with a lower level of Bacteroidetes, had a higher risk of colitis caused by the anti-CTLA-4 therapy [21]. Here, CTLA4 is linked to colitis.